
Sounak Gupta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/78321/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A contemporary guide to chromosomal copy number profiling in the diagnosis of renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 512-524.	0.8	6
2	TERT Copy Number Alterations, Promoter Mutations and Rearrangements in Adrenocortical Carcinomas. Endocrine Pathology, 2022, 33, 304-314.	5.2	4
3	Morphologic overlap between low-grade oncocytic tumorÂand eosinophilic variant of chromophobe renal cell carcinoma. Human Pathology, 2022, 119, 114-116.	1.1	9
4	TERT Promoter Mutations in Keratinizing and Nonkeratinizing Squamous Metaplasia of the Urinary Tract. European Urology Open Science, 2022, 35, 74-78.	0.2	4
5	Biphasic squamoid alveolar renal cell carcinoma: Cytologic features of a rare entity. Annals of Diagnostic Pathology, 2022, 58, 151906.	0.6	0
6	Renal Neoplasia in Polycystic Kidney Disease: An Assessment of Tuberous Sclerosis Complex–associated Renal Neoplasia and PKD1/TSC2 Contiguous Gene Deletion Syndrome. European Urology, 2022, 81, 229-233.	0.9	12
7	Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy. European Urology, 2022, 81, 570-573.	0.9	22
8	Immunohistochemical expression of carbonic anhydrase 9, glucose transporter 1, and paired box 8Âin von Hippel-Lindau disease–related lesions. Human Pathology, 2022, 123, 93-101.	1.1	7
9	Do We Have Sufficient Evidence to Define Prognosis for "Low-grade―Fumarate Hydratase–deficient Renal Cell Carcinoma?. Advances in Anatomic Pathology, 2022, 29, 178-181.	2.4	1
10	Renal Cell Carcinoma With Combined Loss of Fumarate Hydratase and SMARCB1/INI-1. Mayo Clinic Proceedings, 2022, 97, 630-632.	1.4	1
11	Defining Novel DNA Virus-Tumor Associations and Genomic Correlates Using Prospective Clinical Tumor/Normal Matched Sequencing Data. Journal of Molecular Diagnostics, 2022, 24, 515-528.	1.2	12
12	STAT6 Immunopositivity in Solitary Fibrous Tumor of Thyroid Gland. Mayo Clinic Proceedings, 2022, 97, 808-810.	1.4	1
13	Cytogenetics of spermatocytic tumors with a discussion of gain of chromosome 12p in anaplastic variants. Human Pathology, 2022, 124, 85-95.	1.1	2
14	Evaluation of TERT mRNA expression using RNAscope®: A potential histopathologic diagnostic and prognostic tool. Pathology Research and Practice, 2022, 233, 153892.	1.0	2
15	Papillary Renal Cell Carcinoma With "Drop Metastasis―(Tumor Seeding) Involving the Distal Ureter. Mayo Clinic Proceedings, 2022, 97, 1026-1028.	1.4	1
16	Renin Production by Juxtaglomerular Cell Tumors and Clear Cell Renal Cell Carcinoma and the Role of Angiotensin Signaling Inhibitors. Mayo Clinic Proceedings, 2022, 97, 2050-2064.	1.4	2
17	Classification of <i>BRCA2</i> Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay. Clinical Cancer Research, 2022, 28, 3742-3751.	3.2	7
18	Reply to Yang Zhao, Wenda Wang, and Yushi Zhang's Letter to the Editor re: Sounak Gupta, Christine M. Lohse, Ross Rowsey, et al. Renal Neoplasia in Polycystic Kidney Disease: An Assessment of Tuberous Sclerosis Complex–associated Renal Neoplasia and PKD1/TSC2 Contiguous Gene Deletion Syndrome. Eur Urol 2022;81:229–33. European Urology, 2022, , .	0.9	0

#	Article	IF	CITATIONS
19	Postirradiation Angiosarcoma of the Urinary Bladder. Mayo Clinic Proceedings, 2022, 97, 1406-1408.	1.4	1
20	Renal neoplasia with papillary architecture involving the pelvicalyceal system. Human Pathology, 2021, 107, 46-57.	1.1	7
21	A Pan-Cancer Study of Somatic TERT Promoter Mutations and Amplification in 30,773 Tumors Profiled by Clinical Genomic Sequencing. Journal of Molecular Diagnostics, 2021, 23, 253-263.	1.2	20
22	Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. European Urology, 2021, 79, 225-231.	0.9	25
23	Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Modern Pathology, 2021, 34, 1167-1184.	2.9	118
24	Paratesticular Papillary Cystadenoma of theÂEpididymis in the Setting of von Hippel-Lindau. Mayo Clinic Proceedings, 2021, 96, 828-829.	1.4	4
25	New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Modern Pathology, 2021, 34, 1392-1424.	2.9	138
26	Single-cell sequencing links multiregional immune landscapes and tissue-resident TÂcells in ccRCC to tumor topology and therapy efficacy. Cancer Cell, 2021, 39, 662-677.e6.	7.7	179
27	An update on the pathology of collecting duct & papillary renal cell carcinoma with a discussion of SNP-Arrays as an emerging laboratory technique. Urologic Oncology: Seminars and Original Investigations, 2021, , .	0.8	2
28	Renal Neoplasia in Tuberous Sclerosis: A Study of 41 Patients. Mayo Clinic Proceedings, 2021, 96, 1470-1489.	1.4	31
29	Primary Renal Well-Differentiated Neuroendocrine Tumor (Carcinoid) in a Horseshoe Kidney. Mayo Clinic Proceedings, 2021, 96, 1687-1688.	1.4	2
30	The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. Advances in Anatomic Pathology, 2021, 28, 196-208.	2.4	20
31	Comparative molecular analysis of testicular Leydig cell tumors demonstrates distinct subsets of neoplasms with aggressive histopathologic features. Modern Pathology, 2021, 34, 1935-1946.	2.9	15
32	The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. Advances in Anatomic Pathology, 2021, 28, 179-195.	2.4	23
33	Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencing. Human Pathology, 2021, 112, 20-34.	1.1	19
34	Re: Stanley Weng, Renzo G. DiNatale, Andrew Silagy, et al. The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management. Eur Urol 2021;79:468–77. European Urology, 2021, 80, e62-e63.	0.9	2
35	Fumarate Hydratase (FH) c.1431_1433dupAAA (p.Lys477dup) variant is not associated with FH protein deficiency and increased 2SC in two separate patients with renal neoplasia. Human Mutation, 2021, 42, 1362-1364.	1.1	1
36	CD274 (PD-L1) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract. Bladder Cancer, 2021, 7, 1-6.	0.2	2

#	Article	IF	CITATIONS
37	Low-Grade Oncocytic Tumor of Kidney (CK7-Positive, CD117-Negative): Incidence in a single institutional experience with clinicopathological and molecular characteristics. Human Pathology, 2021, 114, 9-18.	1.1	37
38	Renal Neoplasia in Hyperparathyroidism–Jaw Tumor Syndrome. Mayo Clinic Proceedings, 2021, 96, 2730-2731.	1.4	3
39	Assessment of <i>RAS</i> Dependency for <i>BRAF</i> Alterations Using Cancer Genomic Databases. JAMA Network Open, 2021, 4, e2035479.	2.8	9
40	Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey. Journal of Clinical Pathology, 2021, 74, 291-299.	1.0	14
41	Papillary Urothelial Carcinoma. Mayo Clinic Proceedings, 2021, 96, 2746-2747.	1.4	0
42	Assessment of Risk of Hereditary Predisposition in Patients With Melanoma and/or Mesothelioma and Renal Neoplasia. JAMA Network Open, 2021, 4, e2132615.	2.8	4
43	Sarcomatoid renal cell carcinoma: biology, natural history and management. Nature Reviews Urology, 2020, 17, 659-678.	1.9	76
44	Secondary renal neoplasia following chemotherapy or radiation in pediatric patients. Human Pathology, 2020, 103, 1-13.	1.1	10
45	Renal Neoplasia in Cowden Syndrome. Mayo Clinic Proceedings, 2020, 95, 2808-2809.	1.4	5
46	RAS/MAPK Pathway Driver Alterations Are Significantly Associated With Oncogenic KIT Mutations in Germ-cell Tumors. Urology, 2020, 144, 111-116.	0.5	5
47	Tuberous Sclerosis–Associated Renal Neoplasm. Mayo Clinic Proceedings, 2020, 95, 1089-1090.	1.4	1
48	Fumarate Hydratase-Deficient Renal Cell Carcinoma. Mayo Clinic Proceedings, 2020, 95, 619-621.	1.4	3
49	Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 507-516.	2.0	10
50	Defining clear cell papillary renal cell carcinoma in routine clinical practice. Histopathology, 2020, 76, 1093-1095.	1.6	17
51	Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression. Clinical Cancer Research, 2020, 26, 3629-3640.	3.2	30
52	Primary Female Urethral Carcinoma. American Journal of Surgical Pathology, 2020, 44, 1591-1601.	2.1	11
53	Incidence of succinate dehydrogenase and fumarate hydratase–deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC. Human Pathology, 2019, 91, 114-122.	1.1	57
54	RUNX2 (6p21.1) amplification in osteosarcoma. Human Pathology, 2019, 94, 23-28.	1.1	13

#	Article	IF	CITATIONS
55	Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach. Clinical Cancer Research, 2019, 25, 7113-7125.	3.2	69
56	Juxtaglomerular Cell Tumor: A Rare, Curable Cause of Hypertension in a Young Patient. Urology, 2019, 134, 42-44.	0.5	4
57	JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management. Modern Pathology, 2019, 32, 1344-1358.	2.9	49
58	A comparison of adult rhabdomyosarcoma and high-grade neuroendocrine carcinoma of the urinary bladder reveals novel PPP1R12A fusions in rhabdomyosarcoma. Human Pathology, 2019, 88, 48-59.	1.1	2
59	TFEB Expression Profiling in Renal Cell Carcinomas. American Journal of Surgical Pathology, 2019, 43, 1445-1461.	2.1	38
60	JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy. Human Pathology, 2019, 88, 87-91.	1.1	20
61	Next-Generation Sequencing–Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer. Journal of Molecular Diagnostics, 2019, 21, 307-317.	1.2	19
62	Argininosuccinate Synthetase-1 (ASS1) Loss in High-Grade Neuroendocrine Carcinomas of the Urinary Bladder: Implications for Targeted Therapy with ADI-PEG 20. Endocrine Pathology, 2018, 29, 236-241.	5.2	9
63	Testicular Seminoma. Mayo Clinic Proceedings, 2017, 92, e21-e22.	1.4	Ο
64	TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management. Modern Pathology, 2017, 30, 998-1012.	2.9	70
65	Argininosuccinate Synthetase 1 Loss in Invasive Bladder Cancer Regulates Survival through General Control Nonderepressible 2 Kinase–Mediated Eukaryotic Initiation Factor 2α Activity and Is Targetable byÂPegylated Arginine Deiminase. American Journal of Pathology, 2017, 187, 200-213.	1.9	23
66	Composite Pheochromocytoma/Paraganglioma-Ganglioneuroma: A Clinicopathologic Study of Eight Cases with Analysis of Succinate Dehydrogenase. Endocrine Pathology, 2017, 28, 269-275.	5.2	15
67	Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel–Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127). Endocrine Pathology, 2017, 28, 253-268.	5.2	18
68	Hepatocellular Neoplasms Arising in Association With Androgen Use. American Journal of Surgical Pathology, 2016, 40, 454-461.	2.1	32
69	Paratesticular Adenomatoid Tumor. Mayo Clinic Proceedings, 2016, 91, e167-e168.	1.4	3
70	Transforming Growth Factor-β Is an Upstream Regulator of Mammalian Target of Rapamycin Complex 2–Dependent Bladder Cancer Cell Migration and Invasion. American Journal of Pathology, 2016, 186, 1351-1360.	1.9	33
71	Renal Leiomyoma and Leiomyosarcoma. American Journal of Surgical Pathology, 2016, 40, 1557-1563.	2.1	11
72	Urinary Bladder Paragangliomas: Analysis of Succinate Dehydrogenase and Outcome. Endocrine Pathology, 2016, 27, 243-252.	5.2	11

#	Article	IF	CITATIONS
73	Young Female Patient With a Hepatic Adenoma: Determining Risk for Malignant Transformation. Mayo Clinic Proceedings, 2016, 91, e29-e30.	1.4	0
74	Diagnosing a Kidney Tumor. Mayo Clinic Proceedings, 2016, 91, e41-e42.	1.4	0
75	Pancreatic Tumor in a Patient With Parathyroid and Pituitary Disease. Mayo Clinic Proceedings, 2016, 91, e17-e18.	1.4	0
76	High grade neuroendocrine carcinoma of the urinary bladder treated by radical cystectomy: a series of small cell, mixed neuroendocrine and large cell neuroendocrine carcinoma. Pathology, 2015, 47, 533-542.	0.3	26
77	Outcome prediction for patients with renal cell carcinoma. Seminars in Diagnostic Pathology, 2015, 32, 172-183.	1.0	35
78	Magnetic Resonance Elastography. Mayo Clinic Proceedings, 2015, 90, 882-894.	1.4	103
79	Misidentification of Neosartorya pseudofischeri as Aspergillus fumigatus in a Lung Transplant Patient. Journal of Clinical Microbiology, 2014, 52, 2722-2725.	1.8	16
80	Mammalian Target of Rapamycin Complex 2 (mTORC2) Is a Critical Determinant of Bladder Cancer Invasion. PLoS ONE, 2013, 8, e81081.	1.1	35